<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="337634dc-44f4-bc31-e063-6394a90aa9c6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Polymyxin B Sulfate
  <br/>
and
 </content>
      <content styleCode="bold">Trimethoprim
  <br/>
Ophthalmic Solution, USP 
 </content>
      <br/>
(Sterile)
</title>
   <effectiveTime value="20250423"/>
   <setId root="4c7f80fc-257c-498b-bf6e-cfa982f9a3bc"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3376367d-70c1-beba-e063-6394a90ad55f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250423"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-0271" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Polymyxin B Sulfate and Trimethoprim</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Polymyxin B Sulfate and Trimethoprim Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="24208-315" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O40UQP6WCF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SULFURIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="[USP'U]" value="10000"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19371312D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYMYXIN B SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J2VZ07J96K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYMYXIN B</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="E377MF8EQ8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIMETHOPRIM SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AN164J8Y0X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIMETHOPRIM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70518-0271-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170302"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA064120" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_2cc38d33-7c4e-4c43-94a2-e253779acda9">
               <id root="0518ffab-a27a-0aea-e063-6294a90aba8c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL APPLICATION IN THE EYE</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_af5cfa95-3b29-44ec-9bf9-e8dca9d7fac8">
               <id root="0518ffab-a27b-0aea-e063-6294a90aba8c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is a sterile antimicrobial solution for topical ophthalmic use. It has pH of 4.0 to 5.5 and osmolality of 270 to 310 mOsm/kg.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Chemical Names:</content>
                     <br/>  Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine sulfate, is a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula:

 </paragraph>
                  <renderMultiMedia ID="id263" referencedObject="id_c74cbf97-319f-4eda-98cd-5f057357bef7"/>
                  <paragraph>C
 
  <sub>28</sub>H
 
  <sub>38</sub>N
 
  <sub>8</sub>O
 
  <sub>10</sub>S Mol. Wt. 678.72

 </paragraph>
                  <paragraph>Polymyxin B sulfate is the sulfate salt of polymyxin B
 
  <sub>1</sub>and B
 
  <sub>2</sub>which are produced by the growth of
 
  <content styleCode="italics">Bacillus polymyxa</content> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula is:

 </paragraph>
                  <renderMultiMedia ID="id276" referencedObject="id_4751ec26-272b-4b4f-952f-bdb7e22386aa"/>
                  <paragraph>
                     <content styleCode="bold">Each mL contains:</content>Actives: polymyxin B sulfate equal to 10,000 polymyxin B units, trimethoprim sulfate (equivalent to trimethoprim 1 mg); Inactives: purified water, sodium chloride. Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004%

 </paragraph>
               </text>
               <effectiveTime value="20230911"/>
               <component>
                  <observationMedia ID="id_c74cbf97-319f-4eda-98cd-5f057357bef7">
                     <text>Trimethoprim sulfate (Structural formula)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="697ea650-95b5-4814-8821-a99a85314679-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="id_4751ec26-272b-4b4f-952f-bdb7e22386aa">
                     <text>Polymyxin B Sulfate, the sulfate salt of polymyxin B1 and B2 (Structural formula)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="697ea650-95b5-4814-8821-a99a85314679-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_8a4693ed-0e77-4948-a1e0-66becec55d55">
               <id root="0518ffab-a27c-0aea-e063-6294a90aba8c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Trimethoprim is a synthetic antibacterial drug active against a wide variety of aerobic gram-positive and gram-negative ophthalmic pathogens. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductase. This binding is stronger for the bacterial enzyme than for the corresponding mammalian enzyme and therefore selectively interferes with bacterial biosynthesis of nucleic acids and proteins.</paragraph>
                  <paragraph>Polymyxin B, a cyclic lipopeptide antibiotic, is bactericidal for a variety of gram-negative organisms, especially
 
  <content styleCode="italics">Pseudomonas aeruginosa.</content>It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.

 </paragraph>
                  <paragraph>Blood samples were obtained from 11 human volunteers at 20 minutes, 1 hour and 3 hours following instillation in the eye of 2 drops of ophthalmic solution containing 1 mg trimethoprim and 10,000 units polymyxin B per mL. Peak serum concentrations were approximately 0.03 mcg/mL trimethoprim and 1 unit/mL polymyxin B.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Microbiology</content>
                     <br/>  In vitro
 
  <content styleCode="italics"/>studies have demonstrated that the anti-infective components of trimethoprim sulfate and polymyxin B sulfate ophthalmic solution are active against the following bacterial pathogens that are capable of causing external infections of the eye:

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Trimethoprim:</content>Staphylococcus aureus
 
  </content>and
 
  <content styleCode="italics">Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus aegyptius, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis</content>(indole-negative)
 
  <content styleCode="italics">, Proteus vulgaris</content>(indole-positive)
 
  <content styleCode="italics">, Enterobacter aerogenes</content>and
 
  <content styleCode="italics">Serratia marcescens.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Polymyxin B:</content>Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes
 
  </content>and
 
  <content styleCode="italics">Haemophilus influenzae.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_636dbc50-5948-40b5-bea5-4cd024e55195">
               <id root="0518ffab-a27d-0aea-e063-6294a90aba8c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_b9ad8045-dccd-496e-9480-eb901176b3cd">
               <id root="0518ffab-a27e-0aea-e063-6294a90aba8c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_50ae6e6e-3ddf-48c1-b879-4189378d1818">
               <id root="0518ffab-a27f-0aea-e063-6294a90aba8c"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20230911"/>
               <component>
                  <section ID="i4i_precautions_general_id_158db3a3-7c96-4780-a049-660197cd3ed0">
                     <id root="0518ffab-a280-0aea-e063-6294a90aba8c"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>As with other antimicrobial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_info_patients_id_1a285913-a71c-426a-bab5-c8b8e16309b5">
                     <id root="0518ffab-a281-0aea-e063-6294a90aba8c"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_59140f4a-20e0-47c8-b575-c7f241472b70">
                     <id root="0518ffab-a282-0aea-e063-6294a90aba8c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Carcinogenesis:</content>
                           </content>Long-term studies in animals to evaluate carcinogenic potential have not been conducted with polymyxin B sulfate or trimethoprim.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Mutagenesis:</content>
                           </content>Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. In studies at two laboratories no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels after oral administration; at concentrations approximately 1,000 times human plasma levels after oral administration in these same cells, a low level of chromosomal damage was induced at one of the laboratories. Studies to evaluate mutagenic potential have not been conducted with polymyxin B sulfate.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Impairment of Fertility:</content>
                           </content>Polymyxin B sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

 </paragraph>
                        <paragraph>No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_306e6c84-ee78-4d5b-8546-10894f261086">
                     <id root="0518ffab-a283-0aea-e063-6294a90aba8c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20230911"/>
                     <component>
                        <section ID="i4i_teratogenic_id_406945fb-c284-4666-9b2b-0c9bcbafd184">
                           <id root="0518ffab-a284-0aea-e063-6294a90aba8c"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Teratogenic Effects</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>Animal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.</paragraph>
                              <paragraph>Trimethoprim has been shown to be teratogenic in the rat when given in oral doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with oral doses 6 times the human therapeutic dose.</paragraph>
                              <paragraph>While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or oral trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter.</paragraph>
                              <paragraph>Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20230911"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_non_teratogenic_id_04ebd8d3-79ba-4fc4-a556-b0ea8bd9a277">
                           <id root="0518ffab-a285-0aea-e063-6294a90aba8c"/>
                           <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Nonteratogenic Effects</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.</paragraph>
                           </text>
                           <effectiveTime value="20230911"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_39107a76-8784-4abb-acbb-e264f26c0e18">
                     <id root="0518ffab-a286-0aea-e063-6294a90aba8c"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when polymyxin B sulfate and trimethoprim ophthalmic solution is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_48cedab9-654e-43f7-908f-aed09ec2ceec">
                     <id root="0518ffab-a287-0aea-e063-6294a90aba8c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in children below the age of 2 months have not been established (see
 
  <linkHtml href="#_Refi4i_warnings_id_5445cd9c-ea0e-45dc-9">WARNINGS</linkHtml>).

 </paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_84882b0d-8d51-47ee-8be1-7320285969f2">
                     <id root="0518ffab-a288-0aea-e063-6294a90aba8c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_3ff4a575-3e06-4fc5-baea-c748e84bc84f">
               <id root="0518ffab-a289-0aea-e063-6294a90aba8c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The most frequent adverse reaction to polymyxin B sulfate and trimethoprim ophthalmic solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Photosensitivity has been reported in patients taking oral trimethoprim.</paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or
  
   <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                     </content>.

 </paragraph>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_895186ba-3bd0-419f-95fa-e567eef8c386">
               <id root="0518ffab-a28a-0aea-e063-6294a90aba8c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>In mild to moderate infections, instill one drop in the affected eye(s) every 3 hours (maximum of 6 doses per day) for a period of 7 to 10 days.</paragraph>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_4a23e266-0dd7-4ad3-952d-af249cf7630d">
               <id root="0518ffab-a28b-0aea-e063-6294a90aba8c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Polymyxin B sulfate and trimethoprim ophthalmic solution, USP* containing 10,000 polymyxin B units and 1 mg trimethoprim per mL, is supplied in a plastic bottle with a controlled drop tip and a natural cap in the following size:</paragraph>
                  <paragraph>NDC: 70518-0271-00</paragraph>
                  <paragraph>PACKAGING: 1 in 1 CARTON, 10 mL in 1 BOTTLE DROPPER TYPE 0</paragraph>
                  <paragraph/>
                  <paragraph>Storage:</paragraph>
                  <paragraph>Store at 15°C to 25°C (59°F to 77°F). PROTECT FROM LIGHT.</paragraph>
                  <paragraph>*Does not meet USP packaging specification for light resistance.</paragraph>
                  <paragraph>RETAIN IN CARTON UNTIL TIME OF USE.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="id_link_337637c9-2497-9af0-e063-6294a90aff89">
               <id root="337637c9-2496-9af0-e063-6294a90aff89"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: Polymyxin B Sulfate and Trimethoprim</paragraph>
                  <paragraph>GENERIC: Polymyxin B Sulfate and Trimethoprim Sulfate</paragraph>
                  <paragraph>DOSAGE: SOLUTION/ DROPS</paragraph>
                  <paragraph>ADMINSTRATION: OPHTHALMIC</paragraph>
                  <paragraph>NDC: 70518-0271-0</paragraph>
                  <paragraph>PACKAGING: 10 mL in 1 BOTTLE, DROPPER</paragraph>
                  <paragraph>OUTER PACKAGING: 1 in 1 CARTON</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>TRIMETHOPRIM SULFATE 1mg in 1mL</item>
                     <item>POLYMYXIN B SULFATE 10000[USP'U] in 1mL</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>WATER</item>
                     <item>SODIUM CHLORIDE</item>
                     <item>SULFURIC ACID</item>
                     <item>SODIUM HYDROXIDE</item>
                     <item>BENZALKONIUM CHLORIDE</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_33761df6-045e-b338-e063-6394a90acb14"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230911"/>
               <component>
                  <observationMedia ID="img_33761df6-045e-b338-e063-6394a90acb14">
                     <text>MM1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Polymyxin B Sulf - TMP 10000U-1mg-1mL_70518-0271-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>